Day One goes to the market for $150M as biotech kicks off NDA request for pediatric brain cancer drug

Kyle LaHucik

Associate Editor

Day One Biopharmaceuticals will offer up more than 11.5 million shares to nab $150 million in gross proceeds after the biotech last month started a rolling submission for its pediatric brain cancer drug, which had a fresh data drop at last weekend’s ASCO.

The Brisbane, CA-based drug developer will also give investors a chance to buy another 1.73 million shares at the price of $13 apiece, which would send proceeds up another $22.5 million.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Day One goes to the market for $150M as biotech kicks off NDA request for pediatric brain cancer drug

Kyle LaHucik

Associate Editor

Unlock this article instantly by becoming a free subscriber.

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

FDA unveils new rare disease pilot program to increase agency-sponsor communications

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

Data Quality 2.0: The Future of Real-World Evidence

Day One goes to the mar­ket for $150M as biotech kicks off NDA re­quest for pe­di­atric brain can­cer drug

Kyle LaHucik

Associate Editor

Unlock this article instantly by becoming a free subscriber.

De­spite a sum­mer of block­buster rounds, biotech fund­ing is on track to lev­el off at pre-pan­dem­ic norms

FDA rolls out long-await­ed pro­pos­al to over­haul di­ag­nos­tics reg­u­la­tion

How aca­d­e­m­ic cen­ters are try­ing to keep their promis­ing drug dis­cov­er­ies out of the ‘val­ley of death’

FDA un­veils new rare dis­ease pi­lot pro­gram to in­crease agency-spon­sor com­mu­ni­ca­tions

In the race to get type 1 pa­tients off in­sulin, fo­cus turns to cell trans­plants and in­sulin-pro­duc­ing stem cells

Da­ta Qual­i­ty 2.0: The Fu­ture of Re­al-World Ev­i­dence

Day One goes to the market for $150M as biotech kicks off NDA request for pediatric brain cancer drug

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

FDA unveils new rare disease pilot program to increase agency-sponsor communications

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

Data Quality 2.0: The Future of Real-World Evidence